SUBSCRIBE
SUBSCRIBE
News   FDA

Bristol-Myers Squibb Company Obtains Japan Approval For Baraclude, Treatment For Chronic Hepatitis B Patients

August 4, 2006 | 
1 min read

Tokyo, Aug 3, 2006 (JCN) - Bristol-Myers Squibb Japan announced on July 26 that its Baraclude - generic name: entecavir - had been certifiied by Japan’s Health, Labor and Welfare Ministry.

FDA Approvals Asia
Bristol Myers Squibb Company
MORE ON THIS TOPIC
Large yellow signboard on metal frame with the word IPO. Clear sky in the background. Concept of share trading on stock market, capital investment, currency exchange
IPO
Chinese Biotech Ascentage Aims For $134M IPO
January 22, 2025
 · 
2 min read
 · 
Tristan Manalac
FDA sign in front of its building in Maryland
Regulatory
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets
January 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Business
Trump Takes Over, Wegovy Still Trails Zepbound and BioSpace Recaps JPM
January 22, 2025
 · 
1 min read
 · 
Heather McKenzie
Graphic illustration with geometric shapes and textured brush strokes of iconic Cancer awareness and prevention ribbon. Art to be used for Cancer related themes such as support, encouragement, treatment and pre-screening.
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
January 21, 2025
 · 
2 min read
 · 
Tristan Manalac